Use of a pharmacokinetic method for establishing doses of XXXX to treat acute @entity5143 .

@entity1 @entity2544 @entity410 @entity3416 @entity390 @entity712 @entity391 @entity409 @entity5143 @entity1168
A pharmacokinetic method of establishing individualized doses of @entity3416 in @entity1 with acute @entity5143 was evaluated. @entity1 admitted to a hospital who required intravenous @entity3416 for bronchodilation were studied. Blood samples were drawn before treatment for @entity2544 -content measurement. Loading doses were administered intravenously and half-lives and volumes of distribution were determined. Individualized constant-rate infusions based on pharmacokinetic data were then begun. Heart rate, @entity390 , @entity391 , @entity410 , and serum @entity2544 content were monitored during the study. The mean age of the 55 @entity1 in the study was 54.3 years (range: 7 to 87). @entity1 with @entity712 or @entity409 numbered 32; 30 @entity1 were smokers. At approximately 24 hours after the calculated constant-rate infusion was begun, 85% of the @entity1 had therapeutic serum levels of @entity2544 ; 11% of the @entity1 had subtherapeutic levels and 4% had toxic levels. All measured concentrations were between 7.5 and 23.0 microgram/ml. The study method produced significantly more @entity1 in the therapeutic range than would have occurred if previously reported standardized methods had been used (p less than 0.05). Most @entity1 had a @entity1168 after treatment. No other adverse effects occurred that were attributable to i.v. @entity3416 . It is concluded that, for @entity1 in acute @entity5143 , individualizing i.v. @entity3416 doses with @entity1 -specific pharmacokinetic data can increase significantly the number of @entity1 who rapidly attain therapeutic serum @entity2544 levels.
